NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including risks relating to our terminated clinical trials, our remaining contractual commitments, the success of our efforts to maximize the value of our cash and other assets for our shareholders, and levels of future operations and expenditures, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake no obligation to update these forward-looking statements.
CONDENSED STATEMENTS OF OPERATIONS (Unaudited - in thousands, except per share amounts) Three months ended Nine months ended March 31, March 31, 2009 2008 2009 2008 REVENUES Royalty 1,505 2,161 5,590 6,245 Technology sale and collaboration services 1,508 1,523 4,479 5,002 Total revenues 3,013 3,684 10,069 11,247 EXPENSES Research and development 1,857 5,945 17,701 18,822 General and administrative 1,438 1,757 3,970 5,327 Total expenses 3,295 7,702 21,671 24,149 Operating los
|SOURCE Neurobiological Technologies, Inc.|
Copyright©2009 PR Newswire.
All rights reserved